Bruce Booth, D.Phil., a partner at Atlas Venture, astutely observed earlier this year that two key resources fueling the growth of biopharma were until recently somewhat geographically spread among the 10 or so regions of the nation where the industry began to arise a generation ago.
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.
New Enterprise Associates has closed its 16th flagship fund on $3.3 billion, per the Wall Street Journal, the largest venture vehicle ever raised.
ROCKVILLE, Md.–(BUSINESS WIRE)– GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $92.6 million.
The University of Virginia’s Board of Visitors on Friday approved an academic affiliation with the Inova Health System Foundation that includes a research institute and a UVA School of Medicine regional campus.
The governor’s office announces new awards dedicated to bolstering technology research and commercialization around several emerging markets.
The Healthcare Businesswomen’s Association (HBA) announced that its 2017 Woman of the Year is Bahija Jallal, PhD, executive vice president, AstraZeneca, and head of MedImmune. MedImmune is the global biologics research and development arm of AstraZeneca.
Inova Health System and University of Virginia are kicking off their new partnership with $450,000 in seed money to fund nine joint research projects geared toward better predicting, preventing and treating disease.
Business leaders hope to elevate Greater Washington to top three biotech clusters in U.S. Yeah, good luck.
Collaboration across academia, government, non-profits, and the biopharmaceutical industry fosters innovation and groundbreaking discoveries in science and research. During the 2017 BioHealth Capital Region (BHCR) Forum held at our Gaithersburg, Maryland campus, world-renowned speakers and local leaders convened to showcase the benefits of continued collaboration that can help us prevent, treat, and find cures for deadly diseases.